Results 121 to 130 of about 27,758 (263)

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting

Brain Pathology, EarlyView.
Using the Infinium MethylationEPIC v2.0 array and Heidelberg Brain Tumor Classifier v12.8, 24 international laboratories achieved highly reproducible CNS tumor classification (97.9% correct; median β‐correlation r = 0.99), while copy number variation interpretation showed substantial interlaboratory variability, highlighting the need for harmonized CNV
Katrin Mauch‐Mücke, Christin Siewert, Lora Dimitrova, Sandra Pohl, Brendan Osberg, Annika K. Wefers, Julia Lorenz, Tanja Rothhammer‐Hampl, Till Acker, Alonso Barrantes‐Freer, Jean Boutonnat, Bérengère Dadone‐Montaudié, Claire Delbridge, Wolfgang Dietmaier, Sebastian Dintner, Hildegard Dohmen, Matthias Dottermusch, Daniel Erny, Katrin B. M. Frauenknecht, Tobias Goschzik, Patrick N. Harter, Daniela Hirsch, Yanghao Hou, Theo F. J. Kraus, Maggie Lee, Friederike Liesche‐Starnecker, Anne Mc Leer, Linea Melchior, Michael Mittelbronn, Wolf C. Müller, Shalima S. Nair, Julia E. Neumann, Pitt Niehusmann, Nicole Pfarr, Torsten Pietsch, Marco Prinz, Markus Rechsteiner, Regina Reimann, Laveniya Satgunaseelan, Veronica Skarpeteig, Anne J. Skjulsvik, Karl Sotlar, Isabelle Vanden Bempt, Erik Vassella, Katharina J. Weber, Gabriel Wasinger, Andreas Waha, Karen Zwaenepoel, Felix Sahm, Markus J. Riemenschneider, David Capper   +50 more
wiley   +1 more source

Functional interaction between NCYM and MYCN.

, 2014
(A) Relative mRNA levels of NCYM in SK-N-AS MYCN single copy human neuroblastoma cells transfected with MYCN expression vector. mRNA levels were measured by qRT-PCR with β-actin as an internal control.
Mami Yamamoto (505349), Yusuke Suenaga (505343), Mamoru Kato (4346), Shamim Hossain (505347), Wataru Shoji (505350), Makiko Itami (505351), Tatsuhiro Shibata (281685), S. M. Rafiqul Islam (505344), Seiki Haraguchi (370681), Jennifer Alagu (505345), Akira Nakagawara (32581), Yukichi Tanaka (259254), Atsushi Takatori (505352), Yohko Nakamura (32579), Yoshiki Kaneko (505346), Daisuke Matsumoto (505348), Hidetada Kawana (266333), Miki Ohira (221974)   +17 more
core   +1 more source

MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia [PDF]

, 2014
MYCN is an oncogene frequently overexpressed in pediatric solid tumors whereas few evidences suggest his involvement in the pathogenesis of haematologic malignancies.
Togni M, Serravalle S, Astolfi A, Vendemini F, Bressanin D, Tonelli R, Pession A, Urbini M, Martelli AM, Libri V, Masetti R, Paone G, Chiarini F, Melchionda F, Franzoni M, Montemurro L   +15 more
core   +2 more sources

Clinical evaluation of the CrossNN DNA methylation classifier for central nervous system tumors

Brain Pathology, EarlyView.
CrossNN demonstrated non‐inferiority to the Heidelberg CNS Tumor Methylation Classifier. A dual‐classifier approach increased the number of clinically informative classifications with correct tumor type assignment while maintaining a low rate of incorrect predictions.
Jonas Dahnoun, Léon C. van Kempen, Senada Koljenović, Ken Op de Beeck, Tomas Menovsky, Bart Feyen, Melek Ahmed, Anne Sieben, Karen Zwaenepoel   +8 more
wiley   +1 more source

Transcriptional regulation of genes by MYCN in PAX3::FOXO1-positive rhabdomyosarcomas and their roles in cell cycle progression

EJC Paediatric Oncology
Background: MYCN amplification and high expression is associated with pediatric malignancies including neuroblastoma and alveolar rhabdomyosarcoma. MYCN transcription in alveolar rhabdomyosarcomas is driven by a feedback loop with the PAX3::FOXO1 fusion ...
Zoë S. Walters, Daniel Leongamornlert, Barbara Villarejo-Balcells, Carmen Tse, Reuben Pengelly, Ian Titley, Janet Shipley   +6 more
doaj   +1 more source

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

Brain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles, Claudius Jelgersma, Christin Siewert, Brendan Osberg, Simone Schmid, Arend Koch, Eilís Perez, Daniel Teichmann, Martin Misch, Anna‐Gila Karbe, Susanne Ukrow, Patrick N. Harter, Ruth M. Stassart, Peter Vajkoczy, Julia Onken, David Capper   +15 more
wiley   +1 more source

Molecular profiling of pediatric medulloblastoma in Kazakhstan: Genomic alterations, subgroup distribution, and survival

Brain Pathology, EarlyView.
A practical formalin‐fixed, paraffin‐embedded (FFPE)‐based molecular workflow integrating pathology, immunohistochemistry, and genomic profiling provides clinically meaningful subgroup classification of pediatric medulloblastoma and expands molecular evidence from an underrepresented Central Asian population. Abstract Medulloblastoma is the most common
Aidos Bolatov, Askhat Zhakupov, Aizhan Abdikadirova, Malika Sapargaliyeva, Bakytkali Ibraimov, Zhanat Zhalimbetova, Gabit Ólenbay, Berik Zhetpisbayev, Xingzhi Xu, Mirgul Bayanova   +9 more
wiley   +1 more source

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas

Journal of Global Oncology, 2019
PURPOSE: The most significant adverse risk factor for neuroblastoma (NB) is MYCN gene amplification, which strongly associates with high-risk disease.
Teresa Santiago, Nidale Tarek, Fouad Boulos, Caleb Hayes, Sima Jeha, Susana Raimondi, Carlos Rodriguez-Galindo   +6 more
doaj   +1 more source

Drugging MYCN oncogenic signaling through the MYCN-PA2G4 binding interface

, 2019
MYCN is a major driver for the childhood cancer, neuroblastoma, however, there are no inhibitors of this target. Enhanced MYCN protein stability is a key component of MYCN oncogenesis and is maintained by multiple feedforward expression loops involving ...
Daniel Carter (6940148), Jessica Holien (18033589), Jessica Koach (322264), Hassina Massudi (313890)   +3 more
core  

Targeting MYCN in Pediatric Solid Tumors [PDF]

, 2014
MYC proteins are critical drivers of a wide range of cancers, and as transcription factors are generally considered undruggable. MYCN is the neuroblastoma-derived isoform of MYC and is a driving oncogene in neuroblastoma and medulloblastoma, two deadly ...
Meyerowitz, Justin Gabriel
core